834 related articles for article (PubMed ID: 16229851)
21. Injection of paraoxonase 1 (PON1) to mice stimulates their HDL and macrophage antiatherogenicity.
Rosenblat M; Volkova N; Aviram M
Biofactors; 2011; 37(6):462-7. PubMed ID: 22162319
[TBL] [Abstract][Full Text] [Related]
22. Hormone-replacement therapy increases serum paraoxonase arylesterase activity in diabetic postmenopausal women.
Sutherland WH; Manning PJ; de Jong SA; Allum AR; Jones SD; Williams SM
Metabolism; 2001 Mar; 50(3):319-24. PubMed ID: 11230785
[TBL] [Abstract][Full Text] [Related]
23. Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population.
Elkiran ET; Mar N; Aygen B; Gursu F; Karaoglu A; Koca S
BMC Cancer; 2007 Mar; 7():48. PubMed ID: 17362500
[TBL] [Abstract][Full Text] [Related]
24. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1.
Deakin SP; James RW
Clin Sci (Lond); 2004 Nov; 107(5):435-47. PubMed ID: 15265000
[TBL] [Abstract][Full Text] [Related]
25. ApoE induces serum paraoxonase PON1 activity and stability similar to ApoA-I.
Gaidukov L; Viji RI; Yacobson S; Rosenblat M; Aviram M; Tawfik DS
Biochemistry; 2010 Jan; 49(3):532-8. PubMed ID: 20025294
[TBL] [Abstract][Full Text] [Related]
26. Inverse correlation of serum paraoxonase and homocysteine thiolactonase activities and antioxidant capacity of high-density lipoprotein with the severity of cardiovascular disease in persons with type 2 diabetes mellitus.
Lakshman MR; Gottipati CS; Narasimhan SJ; Munoz J; Marmillot P; Nylen ES
Metabolism; 2006 Sep; 55(9):1201-6. PubMed ID: 16919539
[TBL] [Abstract][Full Text] [Related]
27. [The antioxidant function of high density lipoproteins: a new paradigm in atherosclerosis].
Tomás M; Latorre G; Sentí M; Marrugat J
Rev Esp Cardiol; 2004 Jun; 57(6):557-69. PubMed ID: 15225502
[TBL] [Abstract][Full Text] [Related]
28. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F
Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641
[TBL] [Abstract][Full Text] [Related]
29. Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity.
Harangi M; Mirdamadi HZ; Seres I; Sztanek F; Molnár M; Kassai A; Derdák Z; Illyés L; Paragh G
Transl Res; 2009 Apr; 153(4):190-8. PubMed ID: 19304278
[TBL] [Abstract][Full Text] [Related]
30. Di-oleoyl phosphatidylcholine (PC-18:1) stimulates paraoxonase 1 (PON1) enzymatic and biological activities: in vitro and in vivo studies.
Efrat M; Rosenblat M; Mahmood S; Vaya J; Aviram M
Atherosclerosis; 2009 Feb; 202(2):461-9. PubMed ID: 18585720
[TBL] [Abstract][Full Text] [Related]
31. Association of oxidative stress and PON1 with LDL and HDL particle size in middle-aged subjects.
Vekic J; Kotur-Stevuljevic J; Jelic-Ivanovic Z; Spasic S; Spasojevic-Kalimanovska V; Topic A; Zeljkovic A; Stefanovic A; Zunic G
Eur J Clin Invest; 2007 Sep; 37(9):715-23. PubMed ID: 17696961
[TBL] [Abstract][Full Text] [Related]
32. Alteration of HDL functionality and PON1 activities in acute coronary syndrome patients.
Bounafaa A; Berrougui H; Ikhlef S; Essamadi A; Nasser B; Bennis A; Yamoul N; Ghalim N; Khalil A
Clin Biochem; 2014 Dec; 47(18):318-25. PubMed ID: 25218815
[TBL] [Abstract][Full Text] [Related]
33. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome.
Mackness B; Quarck R; Verreth W; Mackness M; Holvoet P
Arterioscler Thromb Vasc Biol; 2006 Jul; 26(7):1545-50. PubMed ID: 16627808
[TBL] [Abstract][Full Text] [Related]
34. Paraoxonase activity in patients with erectile dysfunction.
Ciftci H; Yeni E; Savas M; Verit A; Celik H
Int J Impot Res; 2007; 19(5):517-20. PubMed ID: 17554394
[TBL] [Abstract][Full Text] [Related]
35. Serum paraoxonase activity in uremic predialysis and hemodialysis patients.
Dirican M; Akca R; Sarandol E; Dilek K
J Nephrol; 2004; 17(6):813-8. PubMed ID: 15593056
[TBL] [Abstract][Full Text] [Related]
36. HDL oxidability and its protective effect against LDL oxidation in Type 2 diabetic patients.
Sanguinetti SM; Brites FD; Fasulo V; Verona J; Elbert A; Wikinski RL; Schreier LE
Diabetes Nutr Metab; 2001 Feb; 14(1):27-36. PubMed ID: 11345163
[TBL] [Abstract][Full Text] [Related]
37. Effect of paraoxonase 1 polymorphisms on the response of lipids and lipoprotein-associated enzymes to treatment with fluvastatin.
Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Liamis GL; Kakaidi B; Tselepis AD; Cariolou MA; Elisaf MS
Arch Med Res; 2007 May; 38(4):403-10. PubMed ID: 17416287
[TBL] [Abstract][Full Text] [Related]
38. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity.
James RW; Deakin SP
Free Radic Biol Med; 2004 Dec; 37(12):1986-94. PubMed ID: 15544917
[TBL] [Abstract][Full Text] [Related]
39. Paraoxonase/arylesterase in serum of patients with type II diabetes mellitus.
Juretić D; Motejlkova A; Kunović B; Rekić B; Flegar-Mestrić Z; Vujić L; Mesić R; Lukac-Bajalo J; Simeon-Rudolf V
Acta Pharm; 2006 Mar; 56(1):59-68. PubMed ID: 16613735
[TBL] [Abstract][Full Text] [Related]
40. HDL-associated paraoxonase-1 can redistribute to cell membranes and influence sensitivity to oxidative stress.
Deakin SP; Bioletto S; Bochaton-Piallat ML; James RW
Free Radic Biol Med; 2011 Jan; 50(1):102-9. PubMed ID: 20850524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
